Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Recommendation of “Hold” from Analysts

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been given an average recommendation of “Hold” by the twenty-three research firms that are currently covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a sell rating, eight have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $20.8542.

A number of brokerages have recently issued reports on NTLA. Citizens Jmp reaffirmed a “market outperform” rating and issued a $30.00 price target on shares of Intellia Therapeutics in a research note on Monday, June 15th. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of Intellia Therapeutics in a research note on Monday, June 15th. Robert W. Baird raised their price objective on Intellia Therapeutics from $7.00 to $13.00 and gave the company a “neutral” rating in a report on Monday, April 27th. Evercore raised shares of Intellia Therapeutics to an “outperform” rating and set a $24.00 target price on the stock in a research note on Friday. Finally, Morgan Stanley upped their target price on shares of Intellia Therapeutics from $11.00 to $15.00 and gave the stock an “equal weight” rating in a report on Monday, April 27th.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,641 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $16.78, for a total value of $44,315.98. Following the completion of the sale, the chief accounting officer owned 66,886 shares in the company, valued at approximately $1,122,347.08. This represents a 3.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Edward J. Dulac III sold 4,677 shares of the stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total transaction of $84,186.00. Following the completion of the sale, the executive vice president owned 156,286 shares of the company’s stock, valued at approximately $2,813,148. The trade was a 2.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 3.50% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

Large investors have recently made changes to their positions in the stock. Wesbanco Bank Inc. acquired a new stake in shares of Intellia Therapeutics in the 4th quarter worth $575,000. Canal Insurance CO raised its holdings in shares of Intellia Therapeutics by 130.0% during the 1st quarter. Canal Insurance CO now owns 230,000 shares of the company’s stock worth $2,949,000 after acquiring an additional 130,000 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in shares of Intellia Therapeutics during the 1st quarter valued at about $1,809,000. Massachusetts Financial Services Co. MA acquired a new position in shares of Intellia Therapeutics during the 4th quarter valued at about $318,000. Finally, GSA Capital Partners LLP grew its holdings in shares of Intellia Therapeutics by 210.4% in the fourth quarter. GSA Capital Partners LLP now owns 233,080 shares of the company’s stock valued at $2,095,000 after purchasing an additional 157,989 shares during the period. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Intellia Therapeutics Trading Up 6.2%

NTLA stock opened at $11.94 on Monday. Intellia Therapeutics has a 12-month low of $7.95 and a 12-month high of $28.25. The business’s 50-day moving average is $13.65 and its 200 day moving average is $13.48. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of -3.55 and a beta of 1.81.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, meeting analysts’ consensus estimates of ($0.80). The business had revenue of $7.66 million during the quarter, compared to analysts’ expectations of $12.98 million. Intellia Therapeutics had a negative return on equity of 58.80% and a negative net margin of 672.16%.The business’s revenue was down 46.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.98) earnings per share. As a group, equities analysts forecast that Intellia Therapeutics will post -3.18 EPS for the current fiscal year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.